NDA 021926 · Azurity
Treximet
Naproxen Sodium, Sumatriptan Succinate · Oral
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Apr 15, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
356
90 Phase 3, 11 recruiting
FAERS reports
1,422
464 serious, 24 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. ( 5.1 ) Sumatriptan and Naproxen Sodium Tablets is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history...
What it is approved for
From the label in effect Dec 24, 2024.
Sumatriptan and Naproxen Sodium Tablets is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Sumatriptan and Naproxen Sodium Tablets is a combination of sumatriptan, a serotonin (5-HT) 1b/1d receptor agonist (triptan), and naproxen sodium, a non-steroidal anti-inflammatory drug, indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. ( 1 ) Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. ( 1 ) Not indicated for the prophylactic therapy of migraine attacks. ( 1 ) Not indicated for the treatment of cluster headache. ( 1 ) Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Sumatriptan and Naproxen Sodium Tablets, reconsider the diagnosis of migraine before Sumatriptan and Naproxen Sodium Tablets is administered to treat any subsequent attacks. Sumatriptan and Naproxen Sodium Tablets is not indicated for the prevention of migraine attacks. Safety and effectiveness of Sumatriptan and Naproxen Sodium Tablets have not been established for cluster headache.
Mechanism: Sumatriptan and Naproxen Sodium Tablets contains sumatriptan and naproxen. Sumatriptan binds with high affinity to cloned 5-HT 1B / 1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of neuropeptide release. Sumatriptan and Naproxen Sodium Tablets has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Sumatriptan and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 14, 2015 Supplement 12 · Efficacy · priority review LabelPediatric Written RequestLetter
- Apr 15, 2008 Original approval · Type 4 - New Combination Summary ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
2 products under this application
- TREXIMET · NAPROXEN SODIUM 60MG; SUMATRIPTAN SUCCINATE EQ 10MG BASE · TABLET, ORAL · Discontinued
- TREXIMET · NAPROXEN SODIUM 500MG; SUMATRIPTAN SUCCINATE EQ 85MG BASE · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Naproxen" as an intervention, any sponsor and status, largest first.
- Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00346216 · 24,081 participants · Start Oct 4, 2006 · Primary completion Apr 12, 2016
Drug: celecoxib; Ibuprofen and 1 more · For: Arthritis, Rheumatoid
Sites: Alabaster, Alabama; Bessemer, Alabama; Birmingham, Alabama · 1,066 sites in all
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03161093 · 3,307 participants · Start Aug 17, 2017 · Primary completion Sep 9, 2019
Drug: Fasinumab; Naproxen and 2 more · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Mesa, Arizona; Phoenix, Arizona; Tucson, Arizona · 139 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or HipPivotal-lookingTerminated
PfizerPfizer (PFE)
NCT00809354 · 2,720 participants · Start Feb 12, 2009 · Primary completion Oct 28, 2010
Drug: NSAID; tanezumab and 5 more · For: Osteoarthritis; Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 333 sites in all
- Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)Pivotal-lookingCompleted
Seattle Institute for Biomedical and Clinical ResearchAcademic, hospital or other
NCT00007189 · 2,625 participants · Start Jan 2001 · Primary completion May 2007
Drug: Naproxen Sodium (Aleve); Celecoxib (Celebrex) · For: Alzheimer Disease
Sites: Sun City, Arizona; Tampa, Florida; Baltimore, Maryland · 6 sites in all
- Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of MigrainePivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04384367 · 2,068 participants · Start Dec 30, 2022 · Primary completion Oct 30, 2024
Drug: Rizatriptan 10 mg + Naproxen 550mg; Maxalt 10Mg Tablet and 2 more · For: Migraine
Sites: São Paulo, Brazil · 2 sites in all
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective189
- nausea146
- headache110
- migraine93
- dizziness89
- vomiting77
- pain74
- anxiety72
- fatigue68
- feeling abnormal62
- chest pain56
- dyspnoea51
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 141 |
| 2009 | 246 |
| 2010 | 140 |
| 2011 | 90 |
| 2012 | 102 |
| 2013 | 74 |
| 2014 | 77 |
| 2015 | 103 |
| 2016 | 123 |
| 2017 | 87 |
| 2018 | 75 |
| 2019 | 50 |
| 2020 | 35 |
| 2021 | 24 |
| 2022 | 22 |
| 2023 | 9 |
| 2024 | 10 |
| 2025 | 12 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Treximet (Sumatriptan Succ/Naproxen Sod)
2024 spending
$749K
Beneficiaries
94
450 claims
Per beneficiary
$7,964
$131.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,170,470 |
| 2021 | $1,816,361 |
| 2022 | $1,314,924 |
| 2023 | $1,160,491 |
| 2024 | $748,599 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE, Yeomans ND, Solomon DH, et al. · N Engl J Med 2016 · Multicenter Study, Randomized Controlled Trial
- Naproxen in dysmenorrhoea.
Pauls F · Lancet 1978 · Clinical Trial, Letter
- Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Obeid S, Libby P, Husni E, et al. · Eur Heart J Cardiovasc Pharmacother 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
Bombardier C, Laine L, Reicin A, et al. · N Engl J Med 2000 · Clinical Trial, Comparative Study
- Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa.
Reyes-Uribe L, Wu W, Gelincik O, et al. · Gut 2021 · Clinical Trial, Phase I, Multicenter Study
- [Efficacy of celecoxib, diclofenac, etoricoxib, ibuprofen, ketoprofen and naproxen in low back pain with or without nerve root pain: Systematic review of literature and meta-analysis of randomized controlled trials].
Alfieri P, Landry M, Boussageon R · Therapie 2026 · Systematic Review, Meta-Analysis
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.